Enterprise Value

-19.88M

Cash

100.8M

Avg Qtr Burn

-23.02M

Short % of Float

6.55%

Insider Ownership

14.58%

Institutional Own.

45.49%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Korsuva IV (CR845 IV) Details
Pruritus with chronic kidney disease , Kidney disease

Approved

Quarterly sales

Oral Korsuva (difelikefalin) (CR845) Details
Pruritus with chronic kidney disease , Chronic kidney disease

Phase 3

Update

Oral Korsuva (difelikefalin) (CR845) Details
Chronic pruritus, Pruritus associated with notalgia paresthetica

Phase 2/3

Data readout

Oral Korsuva (difelikefalin) (CR845) Details
Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder

Failed

Discontinued

Oral Korsuva (difelikefalin)(CR845) Details
Inflammatory disease, Skin disease/disorder, Atopic dermatitis, Atopic pruritus

Failed

Discontinued